Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 11 of the 70 sources its claims cite were checked for support.

Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse

Open access
Khoo, Christine M., Carrasco, Daniel R., Bosenberg, Marcus W., Paik, Ji-Hye, DePinho, Ronald A. · 2007 · Proceedings of the National Academy of Sciences

Abstract

The Rb/p16(Ink4a) and p53/p19Arf tumor suppressor pathways have been linked to diverse cancer-relevant processes, including those governing the cellular responses to telomere dysfunction. In this study, we sought to provide direct genetic evidence of a role for the Ink4a/Arf tumor suppressor gene, encoding both p16(Ink4a) and p19(Arf), in modulating the cellular and tissue phenotypes associated with telomere dysfunction by using the mTerc Ink4a/Arf mouse model. In contrast to the rescue associated with p53 deficiency, Ink4a/Arf deficiency did not attenuate the degenerative phenotypes elicited by telomere dysfunction in the late-generation mTerc-/- mice. Furthermore, in contrast to accelerated cancer onset and increased epithelial cancers of late-generation mTerc-/- p53 mutant mice, late-generation mTerc-/- Ink4a/Arf mutant mice experienced a delayed tumor onset and maintained the lymphoma and sarcoma spectrum. Consistent with the negligible role of Ink4a/Arf in the telomere checkpoint response in vivo, late-generation mTerc-/- Ink4a/Arf-/- tissues show activated p53, and derivative tumor cell lines sustain frequent loss of p53 function, whereas all early generation mTerc Ink4a/Arf-/- tumor cell lines remain intact for p53. In addition, the late-generation mTerc-/- Ink4a/Arf-/- tumors showed activation of the alternative lengthening of telomere mechanism, underscoring the need for adaptation to the presence of telomere dysfunction in the absence of p16(Ink4a) and p19(Arf). These observations highlight the importance of genetic context in dictating whether telomere dysfunction promotes or suppresses age-related degenerative conditions as well as the rate of initiation and type of spontaneous cancers.

Overview

CoChat Summary

## TL;DR

Using a telomerase-deficient mouse model crossed with Ink4a/Arf mutants, the study finds that loss of p16Ink4a/p19Arf does not change the degenerative phenotypes caused by telomere dysfunction and does not alter the tumor spectrum. Instead, telomere dysfunction still activates p53, delays tumor onset, and in late tumors selects for p53 pathway defects and ALT activation.

## Key findings

  • In late-generation mTerc-/- mice, the anaphase bridge index (ABI) was comparable across all three Ink4a/Arf genotypes, indicating Ink4a/Arf status does not influence the degree of telomere dysfunction.
  • Late-generation mTerc-/-Ink4a/Arf+/- mice showed tumor death dropping from 84% to 20% and tumor-free latency increasing from 71.6 to 104.9 weeks; late-generation mTerc-/-Ink4a/Arf-/- mice showed tumor death dropping from 98% to 43% and latency increasing from 38.6 to 65.3 weeks.
  • The tumor spectrum did not change with telomere dysfunction: for Ink4a/Arf+/- mice, histiocytic sarcomas/soft tissue sarcomas/lymphomas were 35%/30%/19% in early generations versus 39%/23%/23% in late generations; for Ink4a/Arf-/- mice, the corresponding values were 57%/24%/11% versus 59%/28%/10%.
  • Late-generation mTerc-/-Ink4a/Arf-/- tumors frequently showed compromised p53 checkpoint responses to doxorubicin (6 of 10 cultures) and telomere changes consistent with ALT, including heterogeneous telomeres and signal-free ends rising from 0.9% to 8.7–9.3%.

## Methods

  • Genetic mouse study comparing early- and late-generation mTerc mice with different Ink4a/Arf genotypes; spontaneous tumors and degenerative phenotypes were assessed in vivo.
  • Analyses included ABI measurements in GI crypts, histology, apoptosis and p53 immunohistochemistry, tumor latency/incidence by Kaplan-Meier and log-rank test, and telomere assays (qFISH, telomere repeat fragment Southern).
  • Functional follow-up used cultured tumor cell lines, MEFs, and astrocytes, including doxorubicin-induced p53 checkpoint assays, p53 sequencing, western blotting, and 3T3 growth assays.

## Limitations

  • The paper itself notes that comparisons with prior mTerc-/-p53-/- studies are difficult because those studies used carcinogens and did not analyze normal aging tissues; this limits direct cross-model inference.
  • The text makes evident that the conclusions are based on a mouse model and the tissues/cancer types examined here, so generalization to other genetic contexts or human cancers is not directly tested in this paper.
  • The text also makes evident that some assays used relatively small sample sizes for specific analyses (for example, n=4–7 per group for ABI/apoptosis measurements), which may limit precision in those comparisons.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1073/pnas.0700093104

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

11 Valid · 0 Not valid · 28 Not checked · 62 Own results and interpretations

47 more claims

Create a free account to see all 101 claims and to verify the 4 references still open.

See all claims — free account
  • Probably not a substantial claim. 22
  • It may state two separate claims as one. 33

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 57 references

Research works printed but not linked: 2

  1. L Qi, MA Strong, BO Karim, M Armanios, DL Huso, CW Greider Cancer Res 63, 8188–8196 (2003).
  2. T Kamijo, E van de Kamp, MJ Chong, F Zindy, JA Diehl, CJ Sherr, PJ McKinnon Cancer Res 59, 2464–2469 (1999).

Cited by

See all 52

Metadata

Authors
Khoo, C. M., Carrasco, D. R., Bosenberg, M. W., Paik, J.-H., & DePinho, R. A.
Affiliations
  • Harvard University (US)
  • Brigham and Women's Hospital (US)
  • University of Vermont (US)
Venue
Proceedings of the National Academy of Sciences
Published
2007-03-06
Volume
104
Issue
10
Pages
3931-3936
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2143285081
Cited by
52
References
57
Citations by year
2025: 1 · 2024: 2 · 2022: 1 · 2021: 3 · 2020: 1 · 2018: 3 · 2017: 4 · 2016: 2 · 2015: 2 · 2014: 5 · 2013: 3 · 2012: 5
FWCI
3.34
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Cancer Society
  • Ellison Medical Foundation
  • Damon Runyon Cancer Research Foundation
  • Sidney Kimmel Foundation for Cancer Research
  • Sidney Kimmel Foundation
  • National Institutes of Health
  • National Cancer Institute (U01CA084313, R01CA084628)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
Keywords
p16INK4a, p19ARF, telomere dysfunction, p53, alternative lengthening of telomeres, lymphoma, sarcoma, age-related degeneration
MeSH terms
Animals, Mice, Transgenic, Neoplasms, Neoplasms, Glandular and Epithelial, Phenotype, Time Factors, Genes, Tumor Suppressor, Genes, p53, Tumor Suppressor Protein p53, 3T3 Cells, Telomere, In Situ Hybridization, Fluorescence, Telomerase, Cyclin-Dependent Kinase Inhibitor p16, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. https://app.cochat.ai/papers/10.1073/pnas.0700093104
The paper
Khoo, C. M., Carrasco, D. R., Bosenberg, M. W., Paik, J.-H., & DePinho, R. A. (2007). Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0700093104

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.